5.6 months in the placebo-plus-fulvestrant arm).OS in the cohort withPIK3CAvariants was a secondary end point.
OS data are not yet mature.Very few study participants had received previous CDK4/6 inhibitor therapy.Common toxicities associated with alpelisib included hyperglycemia, diarrhea, nausea, anorexia, and rash.
Careful monitoring and management of hyperglycemia are required during alpelisib use.The FDA approved alpelisib for use in combination with fulvestrant in advancedPIK3CA-mutated, HER2-negative hormone receptorâ€“positive breast cancer after previous endocrine therapy.
PIK3CAvariants were confirmed in 341 participants.